Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARTV Artiva Biotherapeutics	$1.65 +3.5%	$1.95	$1.47 ▼ $17.31	$39.22M	N/A	181,577 shs	78,155 shs
LENZ LENZ Therapeutics	$32.54 +5.1%	$29.04	$16.54 ▼ $38.93	$915.59M	0.42	191,228 shs	103,393 shs
REPL Replimune Group	$9.45 -1.0%	$9.05	$6.44 ▼ $17.00	$724.62M	0.61	867,449 shs	581,094 shs
VIR Vir Biotechnology	$5.49 +1.1%	$5.20	$4.32 ▼ $14.45	$747.87M	1.22	1.36 million shs	395,502 shs

Investing Strategies To Help Grow Your Retirement Income

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARTV Artiva Biotherapeutics	0.00%	+11.90%	-16.07%	-32.58%	+164,499,900.00%
LENZ LENZ Therapeutics	0.00%	+7.80%	+7.38%	+53.61%	+84.23%
REPL Replimune Group	0.00%	+1.29%	-3.08%	+26.68%	+16.81%
VIR Vir Biotechnology	0.00%	+6.19%	+6.60%	-1.61%	-37.33%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ARTV Artiva Biotherapeutics	2.2284 of 5 stars	3.5	0.0	0.0	0.6	1.7	1.3
LENZ LENZ Therapeutics	1.323 of 5 stars	3.6	0.0	0.0	2.1	0.8	0.0
REPL Replimune Group	4.1796 of 5 stars	3.6	1.0	4.5	2.4	2.5	0.6
VIR Vir Biotechnology	3.3632 of 5 stars	3.4	2.0	0.0	2.7	3.3	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ARTV Artiva Biotherapeutics	3.00	Buy	$17.80	982.07% Upside
LENZ LENZ Therapeutics	3.17	Buy	$46.60	43.23% Upside
REPL Replimune Group	3.13	Buy	$20.83	120.46% Upside
VIR Vir Biotechnology	2.86	Moderate Buy	$32.86	498.49% Upside

Current Analyst Ratings Breakdown

Latest ARTV, VIR, REPL, and LENZ Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/3/2025	REPL Replimune Group	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$22.00
6/20/2025	REPL Replimune Group	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight
6/11/2025	ARTV Artiva Biotherapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Buy	$12.00
6/2/2025	REPL Replimune Group	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$14.00 ➝ $22.00
5/22/2025	VIR Vir Biotechnology	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$14.00 ➝ $14.00
5/15/2025	ARTV Artiva Biotherapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$23.00 ➝ $18.00
5/12/2025	VIR Vir Biotechnology	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$19.00 ➝ $14.00
5/8/2025	LENZ LENZ Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$38.00 ➝ $38.00
4/17/2025	VIR Vir Biotechnology	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$28.00 ➝ $21.00
4/16/2025	LENZ LENZ Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$38.00 ➝ $38.00
4/14/2025	LENZ LENZ Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight ➝ Overweight	$38.00 ➝ $51.00

(Data available from 7/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ARTV Artiva Biotherapeutics	$250K	160.29	N/A	N/A	$7.68 per share	0.21
LENZ LENZ Therapeutics	N/A	N/A	N/A	N/A	$7.42 per share	N/A
REPL Replimune Group	N/A	N/A	N/A	N/A	$5.40 per share	N/A
VIR Vir Biotechnology	$74.21M	10.23	N/A	N/A	$8.35 per share	0.66

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ARTV Artiva Biotherapeutics	-$65.37M	N/A	0.00	N/A	N/A	N/A	-75.95%	-39.51%	8/7/2025 (Estimated)
LENZ LENZ Therapeutics	-$49.77M	-$1.77	N/A	N/A	N/A	N/A	-23.74%	-22.65%	8/13/2025 (Estimated)
REPL Replimune Group	-$247.30M	-$3.07	N/A	N/A	N/A	N/A	-57.98%	-45.21%	8/14/2025 (Estimated)
VIR Vir Biotechnology	-$521.96M	-$4.22	N/A	N/A	N/A	-2,769.04%	-47.46%	-39.33%	7/30/2025 (Estimated)

Latest ARTV, VIR, REPL, and LENZ Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/22/2025	Q4 2025	REPL Replimune Group	-$0.75	-$0.82	-$0.07	-$0.82	N/A	N/A
5/8/2025	Q1 2025	ARTV Artiva Biotherapeutics	-$0.68	-$0.83	-$0.15	-$0.83	N/A	N/A
5/7/2025	Q1 2025	LENZ LENZ Therapeutics	-$0.55	-$0.53	+$0.02	-$0.53	N/A	N/A
5/7/2025	Q1 2025	VIR Vir Biotechnology	-$0.83	-$0.88	-$0.05	-$0.88	$8.59 million	$3.03 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ARTV Artiva Biotherapeutics	N/A	N/A	N/A	N/A	N/A
LENZ LENZ Therapeutics	N/A	N/A	N/A	N/A	N/A
REPL Replimune Group	N/A	N/A	N/A	N/A	N/A
VIR Vir Biotechnology	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ARTV Artiva Biotherapeutics	N/A	13.93	13.93
LENZ LENZ Therapeutics	N/A	23.09	23.09
REPL Replimune Group	0.17	7.95	7.95
VIR Vir Biotechnology	N/A	6.79	6.79

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ARTV Artiva Biotherapeutics	N/A
LENZ LENZ Therapeutics	54.32%
REPL Replimune Group	92.53%
VIR Vir Biotechnology	65.32%

Insider Ownership

Company	Insider Ownership
ARTV Artiva Biotherapeutics	21.40%
LENZ LENZ Therapeutics	6.90%
REPL Replimune Group	8.80%
VIR Vir Biotechnology	16.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ARTV Artiva Biotherapeutics	81	24.36 million	19.15 million	N/A
LENZ LENZ Therapeutics	110	28.15 million	26.20 million	N/A
REPL Replimune Group	210	77.09 million	70.30 million	Optionable
VIR Vir Biotechnology	580	138.24 million	116.12 million	Optionable

ARTV, VIR, REPL, and LENZ Headlines

Recent News About These Companies

Vicki L. Sato Sells 22,000 Shares of Vir Biotechnology, Inc. (NASDAQ:VIR) Stock

July 3 at 7:09 AM | insidertrades.com

Insider Selling: Vir Biotechnology, Inc. (NASDAQ:VIR) Director Sells 22,000 Shares of Stock

July 2, 2025 | marketbeat.com

Vir Biotechnology, Inc. (NASDAQ:VIR) Shares Sold by State of Alaska Department of Revenue

June 30, 2025 | marketbeat.com

Is Vir Biotechnology (NASDAQ:VIR) In A Good Position To Deliver On Growth Plans?

June 25, 2025 | finance.yahoo.com

Vir Biotechnology, Inc. (NASDAQ:VIR) Given Consensus Rating of "Moderate Buy" by Brokerages

June 12, 2025 | marketbeat.com

Bank of America Corp DE Has $1.42 Million Stake in Vir Biotechnology, Inc. (NASDAQ:VIR)

June 6, 2025 | marketbeat.com

Janet Napolitano Sells 3,200 Shares of Vir Biotechnology, Inc. (NASDAQ:VIR) Stock

June 3, 2025 | insidertrades.com

Vir Biotech at TD Cowen’s Summit: Strategic Focus on HDV and Oncology

May 29, 2025 | investing.com

Vir Biotechnology to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference 2025

May 28, 2025 | businesswire.com

Gilead pays partner Hookipa $10M to take over HBV, HIV therapeutic vaccine programs

May 22, 2025 | fiercebiotech.comF

Vir Biotechnology Stock: A Deep Dive Into Analyst Perspectives (6 Ratings)

May 22, 2025 | benzinga.com

Vir’s hepatitis B combo falls short in Phase II trial

May 12, 2025 | msn.com

Vir Biotechnology to Participate in Bank of America Securities 2025 Healthcare Conference

May 12, 2025 | businesswire.com

Vir Biotechnology First Quarter 2025 Earnings: Revenues Disappoint

May 10, 2025 | finance.yahoo.com

Why Vir Biotechnology, Inc.’s (VIR) Stock Is Down 5.45%

May 10, 2025 | aaii.comA

Q1 2025 Vir Biotechnology Inc Earnings Call

May 10, 2025 | finance.yahoo.com

Vir's 'functional cure' candidate for hepatitis B misses mark in phase 2

May 10, 2025 | fiercebiotech.comF

Vir Biotechnology Announces Preliminary 24-Week Post-End of Treatment Data for Tobevibart and Elebsiran Combinations in Chronic Hepatitis B From the MARCH Study

May 9, 2025 | businesswire.com

Vir Biotechnology’s Earnings Call: Mixed Sentiment Amid Progress

May 8, 2025 | tipranks.com

Vir Biotechnology: Tobevibart Combination Pushing Forward For Needed HDV Treatment

May 8, 2025 | seekingalpha.com

Vir Biotechnology announces initiation of ECLIPSE Phase III program for hepatitis delta virus

May 8, 2025 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Why BigBear.ai Could Rally 100% and Catch Palantir Soon
By Gabriel Osorio-Mazilli | June 30, 2025
View Why BigBear.ai Could Rally 100% and Catch Palantir Soon
3 Tech Stocks You Can't Miss in This Market Cycle
By Gabriel Osorio-Mazilli | June 17, 2025
View 3 Tech Stocks You Can't Miss in This Market Cycle
Payment Giants Slide on Stablecoin Buzz—Is Now the Time to Buy?
By Gabriel Osorio-Mazilli | June 23, 2025
View Payment Giants Slide on Stablecoin Buzz—Is Now the Time to Buy?
Whiplash for Investors: AeroVironment's Confusing Stock Signals
By Jeffrey Neal Johnson | July 2, 2025
View Whiplash for Investors: AeroVironment's Confusing Stock Signals
AeroVironment Will Hit New Highs This Year: Bull Flag Confirmed
By Thomas Hughes | June 25, 2025
View AeroVironment Will Hit New Highs This Year: Bull Flag Confirmed

ARTV, VIR, REPL, and LENZ Company Descriptions

Artiva Biotherapeutics NASDAQ:ARTV

$1.64 +0.06 (+3.46%)

As of 07/3/2025 03:29 PM Eastern

Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company's lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma. It also develops AB-201, an allogeneic anti- human epidermal growth factor receptor 2 chimeric antigen receptor (CAR)-NK cell product candidate; and AB-205, an allogeneic anti-CD5 CAR-NK cell product candidate. The company was incorporated in 2019 and is headquartered in San Diego, California.

LENZ Therapeutics NASDAQ:LENZ

$32.53 +1.58 (+5.09%)

Closing price 07/3/2025 03:28 PM Eastern

Extended Trading

$32.53 0.00 (0.00%)

As of 07/3/2025 04:19 PM Eastern

LENZ Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.

Replimune Group NASDAQ:REPL

$9.45 -0.10 (-1.05%)

Closing price 07/3/2025 03:03 PM Eastern

Extended Trading

$9.48 +0.03 (+0.26%)

As of 07/3/2025 04:51 PM Eastern

Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma. The company is also developing RP2, which is in Phase I clinical trials to express an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trial to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.

Vir Biotechnology NASDAQ:VIR

$5.49 +0.06 (+1.10%)

Closing price 07/3/2025 03:36 PM Eastern

Extended Trading

$5.42 -0.07 (-1.18%)

As of 07/3/2025 04:54 PM Eastern

Vir Biotechnology, Inc., an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV). The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune, LLC; collaboration with WuXi Biologics (Hong Kong) Limited and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A, as well as license agreement with Sanofi for three clinical-stage masked T-cell engagers (TCEs) and exclusive use of the protease-cleavable masking platform for oncology and infectious diseases. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. The company was incorporated in 2016 and is headquartered in San Francisco, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time